HK1059789A1 - CD4-gamma2 and cd4-lgg2 chimeras. - Google Patents

CD4-gamma2 and cd4-lgg2 chimeras.

Info

Publication number
HK1059789A1
HK1059789A1 HK04101540A HK04101540A HK1059789A1 HK 1059789 A1 HK1059789 A1 HK 1059789A1 HK 04101540 A HK04101540 A HK 04101540A HK 04101540 A HK04101540 A HK 04101540A HK 1059789 A1 HK1059789 A1 HK 1059789A1
Authority
HK
Hong Kong
Prior art keywords
gamma2
lgg2
chimeras
provides
expression vector
Prior art date
Application number
HK04101540A
Other languages
English (en)
Inventor
Paul J Maddon
Gary A Beaudry
Original Assignee
Progenics Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc filed Critical Progenics Pharm Inc
Publication of HK1059789A1 publication Critical patent/HK1059789A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK04101540A 1991-02-08 2004-03-02 CD4-gamma2 and cd4-lgg2 chimeras. HK1059789A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65368491A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
HK1059789A1 true HK1059789A1 (en) 2004-07-16

Family

ID=24621912

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101540A HK1059789A1 (en) 1991-02-08 2004-03-02 CD4-gamma2 and cd4-lgg2 chimeras.

Country Status (10)

Country Link
US (2) US6451313B1 (xx)
EP (2) EP1340769B1 (xx)
JP (1) JP3670276B2 (xx)
AT (1) ATE288923T1 (xx)
AU (1) AU660662B2 (xx)
CA (1) CA2080226C (xx)
DE (1) DE69233480T2 (xx)
ES (1) ES2237727T3 (xx)
HK (1) HK1059789A1 (xx)
WO (1) WO1992013947A1 (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
JP3670276B2 (ja) * 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ
CA2141673A1 (en) 1992-08-07 1994-02-17 Graham P. Allaway Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof
US5817767A (en) * 1993-02-24 1998-10-06 Progenics Pharmaceuticals, Inc. Synergistic composition of CD4-based protein and anti-HIV-1 antibody, and methods of using same
WO1996002575A1 (en) * 1994-07-13 1996-02-01 Progenics Pharmaceuticals, Inc. Articles of manufacture for removing hiv-1 from a sample, and methods of using same
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
CN103212084B (zh) * 2003-11-13 2018-07-13 韩美科学株式会社 含有免疫球蛋白fc区作为载体的药物组合物
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
AU2005222641B2 (en) * 2004-03-15 2011-04-07 Nektar Therapeutics Polymer-based compositions and conjugates of HIV entry inhibitors
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
EP2025762A3 (en) 2006-01-17 2009-09-30 Health Research Inc. Heteroduplex tracking assay
US20080051503A1 (en) * 2006-08-28 2008-02-28 The Goodyear Tire & Rubber Company Method of mixing fiber loaded compounds using a Y-mix cycle
JP5563572B2 (ja) 2008-07-23 2014-07-30 ハンミ サイエンス カンパニー リミテッド 三末端官能基を有する非ペプチド性重合体を用いた生理活性ポリペプチド薬物結合体
WO2011076781A1 (en) * 2009-12-22 2011-06-30 Novartis Ag Tetravalent cd47-antibody constant region fusion protein for use in therapy
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
US10010498B2 (en) 2014-06-04 2018-07-03 Acceleron Pharma Inc. Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
WO2015187977A1 (en) * 2014-06-04 2015-12-10 Acceleron Pharma, Inc. Methods and compositions for treatment of disorders with follistatin polypeptides
WO2016154601A1 (en) 2015-03-26 2016-09-29 Acceleron Pharma Inc. Follistatin-related fusion proteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
DE3751751T2 (de) 1986-08-21 1996-10-17 Univ Columbia Für das t-zell oberflächenprotein t4 kodierende dna und verwendung von t4-fragmenten bei der behandlung von aids
JPH02501192A (ja) 1987-09-04 1990-04-26 バイオジェン インコーポレイテッド 可溶性ｔ４蛋白を製造するためのｄｎａ配列、組換ｄｎａ分子および方法
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
IL87902A0 (en) 1987-10-08 1989-03-31 Dana Farber Cancer Inst Inc Soluble human cd4 fragments and applications thereof
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
IL91070A (en) * 1988-07-23 1995-03-30 Us Commerce Cytotoxic agents against certain viral infections
JPH02107393A (ja) * 1988-10-18 1990-04-19 Asahi Chem Ind Co Ltd 排水中の塩素系溶剤の除去方法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
EP0739904A1 (en) * 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
WO1992013559A1 (en) * 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CD4-GAMMA1 AND CD4-IgG1 CHIMERAS
JP3670276B2 (ja) * 1991-02-08 2005-07-13 プロゲニクス・ファーマスーティカルズ、インコーポレイテッド ＣＤ４― ガンマ・２キメラ及びＣＤ４ ― ＩｇＧ２・キメラ
EP0571536A4 (en) * 1991-02-12 1995-03-22 Univ Colorado State Res Found REAGENTS AND METHODS FOR IDENTIFYING VACCINES.
CA2141673A1 (en) * 1992-08-07 1994-02-17 Graham P. Allaway Non-peptidyl moiety-conjugated cd4-gamma2 and cd4-igg2 immunoconjugates, and uses thereof

Also Published As

Publication number Publication date
JP3670276B2 (ja) 2005-07-13
EP0528011A4 (en) 1993-06-30
EP1340769B1 (en) 2005-02-09
JPH05507854A (ja) 1993-11-11
CA2080226A1 (en) 1992-08-09
EP0528011A1 (en) 1993-02-24
ATE288923T1 (de) 2005-02-15
ES2237727T3 (es) 2005-08-01
EP1340769A1 (en) 2003-09-03
AU1440092A (en) 1992-09-07
WO1992013947A1 (en) 1992-08-20
DE69233480D1 (de) 2005-03-17
US6187748B1 (en) 2001-02-13
AU660662B2 (en) 1995-07-06
US6451313B1 (en) 2002-09-17
CA2080226C (en) 2004-05-04
DE69233480T2 (de) 2006-01-05

Similar Documents

Publication Publication Date Title
HK1059789A1 (en) CD4-gamma2 and cd4-lgg2 chimeras.
HK1017883A1 (en) Antiparasitic marcfortines
EP0616488A3 (en) Light emitting elements.
EP0628590A3 (en) Organopolysiloxane-side-substituted polyimide.
PL332541A1 (en) D-olanzapin dihydrate
EP0632550A3 (en) Modulation of laser diodes.
EP0680198A3 (en) Printer with optical feedback loop.
GR3024454T3 (en) Axially-engaged, abrasion-resistant split sprocket assembly.
EP0610648A3 (en) Communication device with multi-level code.
EP0631169A3 (en) Optical modulation device.
EP0658793A4 (en) OPTICAL MODULATOR.
EP0590595A3 (en) Rubber composition based on oil resistant polysiloxane.
GR3007304T3 (xx)
YU32590A (en) Agents for improving chain for p-phenylenmethylendi-izo-cianatic prepolymers for cast polyurethanic elastomers
EP0650112A3 (de) Konstantstromquelle.
EP0627772A3 (en) Light emitting device from AlGaInP.
GR3006694T3 (xx)
EP0606092A3 (en) Diode laser element.
EP0685559A4 (en) FROM PLANT COMBUSABLE PHOSPHOLIPASE D GEN.
EP0556607A3 (en) Distributed feedback laser diodes with selectively placed lossy sections
EP0632299A3 (de) Optoelektronisches Bauelement mit Rückkopplungsgitter.
EP0632429A3 (en) Vector quantizer.
EP0611105A3 (en) Power source.
EP0632554A3 (en) Semiconductor light emitting device.
EP0614257A3 (en) Profit-led diode laser.

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE FILING DATE OF THE PRIORITY APPLICATION FROM 08.05.1991 TO 08.02.1991

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090210